News Sentiment

PTGX sentiment intelligence

Protagonist Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 63 Constructive news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 140.91 Week of 17 Jul 2026
Weighted tone 63/100

Constructive news tone

Market reaction News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update

81/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+7.2% over one week, +24.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Protagonist Therapeutics stock hits all-time high at 141.79 USD By Investing.com

Market Reaction

News confirmed by price

74/100 confidence

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update 81/100 classification
One-week reaction 7.2% Price confirming higher
Trend fit Trend active 24.9% over four weeks
Fair value 170.3% Materially above fair value
Sentiment confirms active trend Positive but stretched

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 28
Neutral 30
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
simplywall.st 8
Stock Titan 6
Quartr 5
TradingView 5
AlphaStreet 3
Investing.com Canada 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 14
Analyst action 8
Regulatory and legal 2
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
TradingView Direct company coverage

Enterprise value to EBIT forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX

This article provides financial information for Protagonist Therapeutics, Inc. (NASDAQ: PTGX), specifically focusing on its enterprise value to EBIT forward. It appears to be a stub or a data page from TradingView, displaying the current market status and various navigation optio

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 19:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX

The article provides the enterprise value to revenue forward for Protagonist Therapeutics, Inc. (NASDAQ: PTGX). It presents basic financial and market information for the company as listed on TradingView, covering its Nasdaq Stock Market data.

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 15:43
Source
TradingView
Investing.com Direct company coverage

Protagonist Therapeutics Inc stock hits all-time high at 131.99 USD

Protagonist Therapeutics Inc. (PTGX) stock has reached an all-time high of $131.99, currently trading at $132.27, showcasing a significant 163.93% increase over the past year. Despite analysts viewing the stock as overvalued, they predict profitability this year with forecasted e

Tone
Positive 72/100
Event
Market update
Published
06 Jul 2026 14:43
Source
Investing.com